Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multi-center, Dose-Escalation Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity of KN046 in Subjects With Advanced Solid Tumors

NCT03529526 is registered in ClinicalTrials.gov with Alphamab (Australia) Co Pty Ltd. as lead sponsor.

NCT NCT03529526
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03529526 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multi-center, Dose-Escalation Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity of KN046 in Subjects With Advanced Solid Tumors
Lead sponsor
Alphamab (Australia) Co Pty Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
May 21, 2018
Completion date
March 30, 2020
Enrollment
21 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors